Kiora Pharmaceuticals Reports $2.42 Million Net Loss in Q1 2026, Increases Cash Reserves

Kiora Pharmaceuticals, Inc. reported a net loss of $2.42 million for the first quarter of 2026, compared to a net loss of $2.19 million for the same period in 2025. The company's total operating expenses increased to $2.51 million from $2.33 million year-over-year, primarily driven by higher general and administrative costs, which rose by $122,869 due to increased personnel and professional service expenses. Research and development expenses decreased by $408,162, reflecting a reduction in preclinical and manufacturing costs, partially offset by increased clinical trial expenses.

In terms of financial position, Kiora's cash and cash equivalents increased to $10.96 million as of March 31, 2026, up from $8.70 million at the end of 2025. The company also reported short-term investments of $2.92 million, down from $8.39 million at the end of the previous year. Total assets decreased to $21.23 million from $24.25 million, while total liabilities fell to $7.29 million from $8.13 million, indicating a reduction in both current and non-current liabilities.

Kiora has made strategic advancements, including the initiation of a Phase 2 clinical trial for its lead product candidate, KIO-301, aimed at treating retinitis pigmentosa. The company also entered into a collaboration agreement with Théa Open Innovation, which provided Kiora with a $16 million upfront payment and potential milestone payments totaling up to $285 million. Additionally, Kiora secured a non-refundable option fee of $1.25 million from Senju Pharmaceutical for exclusive rights to KIO-301 in certain Asian markets.

Operationally, Kiora's collaboration with Théa has allowed it to focus on advancing its clinical trials while managing costs through reimbursement agreements. The company reported a decrease in collaboration credits, which are tied to research and development expenses reimbursed by Théa. As of March 31, 2026, Kiora had a total of 3,993,469 shares outstanding, reflecting an increase from the previous quarter, and it continues to explore additional financing options to support its ongoing operations and product development.

Looking ahead, Kiora anticipates needing further financing to support its operations and product commercialization efforts. The company expects to have sufficient cash to fund its planned operations into late 2028, bolstered by recent financing activities. However, it acknowledges the potential challenges in securing additional capital on favorable terms, which could impact its ability to execute its business strategy effectively.